IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 1.94 SEK -0.72% Market Closed
Market Cap: 164.6m SEK

Operating Margin
IRLAB Therapeutics AB

-87.1%
Current
-689%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-87.1%
=
Operating Profit
-74.5m
/
Revenue
85.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
IRLAB Therapeutics AB
STO:IRLAB A
164.8m SEK
-87%
US
Eli Lilly and Co
NYSE:LLY
999.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
501.2B USD
27%
CH
Roche Holding AG
SIX:ROG
254.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.1B GBP
24%
CH
Novartis AG
SIX:NOVN
206.7B CHF
33%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.4B USD
29%
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
164.8m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
9.01 SEK
Undervaluation 78%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-87.1%
=
Operating Profit
-74.5m
/
Revenue
85.6m
What is the Operating Margin of IRLAB Therapeutics AB?

Based on IRLAB Therapeutics AB's most recent financial statements, the company has Operating Margin of -87.1%.

Back to Top